Acuta Capital Partners, LLC Unicycive Therapeutics, Inc. Transaction History
Acuta Capital Partners, LLC
- $52.7 Million
- Q1 2025
A detailed history of Acuta Capital Partners, LLC transactions in Unicycive Therapeutics, Inc. stock. As of the latest transaction made, Acuta Capital Partners, LLC holds 2,352,887 shares of UNCY stock, worth $1.29 Million. This represents 2.54% of its overall portfolio holdings.
Number of Shares
2,352,887
Previous 2,303,000
2.17%
Holding current value
$1.29 Million
Previous $1.82 Million
26.28%
% of portfolio
2.54%
Previous 2.59%
Shares
3 transactions
Others Institutions Holding UNCY
# of Institutions
31Shares Held
59.9MCall Options Held
0Put Options Held
0-
Vivo Capital, LLC Palo Alto, CA11.4MShares$6.25 Million1.76% of portfolio
-
Great Point Partners LLC Greenwich, CT11MShares$6.04 Million3.87% of portfolio
-
Octagon Capital Advisors LP New York, NY10MShares$5.5 Million1.9% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT9.39MShares$5.17 Million0.24% of portfolio
-
Logos Global Management LP San Francisco, CA5.08MShares$2.79 Million0.56% of portfolio
About Unicycive Therapeutics, Inc.
- Ticker UNCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,052,500
- Market Cap $8.28M
- Description
- Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...